Literature DB >> 29616123

Overexpression and clinical significance of IBP in epithelial ovarian carcinoma.

Yingjuan Xu1, Yangming Hou2, Tianbo Liu1, Ge Lou1.   

Abstract

Interferon regulatory factor-4 binding protein (IBP) is as a type of ρ GTPase suggested to serve an important role in tumor occurrence and development through the effects of cytoskeletal remodeling, and cell conduction mechanism. IBP is widely expressed in the immune system and expressed in several types of tumors. However, its expression and prognostic value in epithelial ovarian carcinoma (EOC) remain unclear. The present study aimed to investigate the expression of IBP in EOC, and its effect on clinicopathological variables and prognosis. A total of 107 and 30 cases of epithelial ovarian carcinoma and benign ovarian disease tissue sections, respectively, were examined using immunohistochemistry. The results indicated that the IBP expression status was negative or markedly weak in normal tissues, but highly expressed in EOC tissues. A significant association was observed between IBP overexpression and various clinicopathological factors, including advanced International Federation of Gynecology and Obstetrics stage (P<0.001), poor histologic grade (P=0.002), peritoneal carcinomatosis (P<0.001), lymph-node metastasis (P=0.023) and recurrence (P<0.001). Multivariate Cox regression analysis additionally suggested that IBP overexpression was an independent factor affecting recurrence-free survival [hazard ratio (HR)=4.099; 95% confidence interval (CI), 2.209-7.606; P<0.001) and overall survival (HR=2.317; 95% CI, 1.484-3.617; P<0.001) in patients with EOC. The results of the present study demonstrated that IBP overexpression may be associated with tumor development and progression in EOC, and therefore may serve as a novel target for treating this disease.

Entities:  

Keywords:  epithelial ovarian carcinoma; immunohistochemistry; interferon regulatory factor-4 binding protein; prognosis; survival

Year:  2018        PMID: 29616123      PMCID: PMC5876473          DOI: 10.3892/ol.2018.8125

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  Motility and invasion are differentially modulated by Rho family GTPases.

Authors:  J Banyard; B Anand-Apte; M Symons; B R Zetter
Journal:  Oncogene       Date:  2000-01-27       Impact factor: 9.867

Review 2.  Regulation of cell function by Rho family GTPases.

Authors:  G M Bokoch
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  Cooperation of DEF6 with activated Rac in regulating cell morphology.

Authors:  Tsutomu Oka; Sayoko Ihara; Yasuhisa Fukui
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

4.  Def-6, a guanine nucleotide exchange factor for Rac1, interacts with the skeletal muscle integrin chain alpha7A and influences myoblast differentiation.

Authors:  Thomas Samson; Carola Will; Alexander Knoblauch; Lisa Sharek; Klaus von der Mark; Keith Burridge; Viktor Wixler
Journal:  J Biol Chem       Date:  2007-04-02       Impact factor: 5.157

5.  Ectopically expressed IBP promotes cell proliferation in oral squamous cell carcinoma.

Authors:  Cong-Xiang Jian; Ming-Zhen Yang; Peng Li; Jian Xiong; Zhu-Jun Zhang; Chen-Jun Li; An Chen; Chuan-Min Hu; Ji-Xiang Zhou; Shu-Hui Li
Journal:  Cancer Invest       Date:  2012-10-22       Impact factor: 2.176

6.  Prevalence of cysts in epithelial ovarian cancer.

Authors:  Eva Kolwijck; Charlotte Lybol; Johan Bulten; Jos H A Vollebergh; Ron A Wevers; Leon F A G Massuger
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-03-29       Impact factor: 2.435

7.  The ectopic expression of IFN regulatory factor 4-binding protein is correlated with the malignant behavior of human breast cancer cells.

Authors:  Peng Li; Zhujun Zhang; Qingliang Wang; Shuhui Li; Yang Zhang; Xiuwu Bian; An Chen; Chuanmin Hu
Journal:  Int Immunopharmacol       Date:  2009-04-22       Impact factor: 4.932

8.  Overexpression of the Interferon regulatory factor 4-binding protein in human colorectal cancer and its clinical significance.

Authors:  Zhujun Zhang; Qingliang Wang; Peng Li; Yu Zhou; Shuhui Li; Weijing Yi; An Chen; Peiyan Kong; Chuanmin Hu
Journal:  Cancer Epidemiol       Date:  2009-07-10       Impact factor: 2.984

Review 9.  Rho GTPases in cancer cell biology.

Authors:  Francisco M Vega; Anne J Ridley
Journal:  FEBS Lett       Date:  2008-05-05       Impact factor: 4.124

10.  SLAT/Def6 plays a critical role in the development of Th17 cell-mediated experimental autoimmune encephalomyelitis.

Authors:  Ann J Canonigo-Balancio; Camille Fos; Thomas Prod'homme; Stéphane Bécart; Amnon Altman
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

View more
  2 in total

1.  Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma.

Authors:  Qiao Zhang; Guo-Sheng Zhao; Ya Cao; Xue-Feng Tang; Qiu-Lin Tan; Lu Lin; Qiao-Nan Guo
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

2.  High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.

Authors:  Zhen-Peng Zhu; Lan-Ruo Lin; Tong-De Lv; Chun-Ru Xu; Tian-Yu Cai; Jian Lin
Journal:  Oncol Rep       Date:  2020-08-18       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.